#ESMO25: Exelixis says TKI extended survival in Phase 3 colorectal cancer trial news2025-10-20T06:30:48+00:00October 20th, 2025|Endpoints News|
#ESMO25: Sanofi, Orano Med’s radiopharmaceutical looks competitive in rare cancernews2025-10-20T06:30:11+00:00October 20th, 2025|Endpoints News|
FDA approves Roche’s CD20 antibody Gazyva for lupus nephritisnews2025-10-20T05:00:46+00:00October 20th, 2025|Endpoints News|
#ESMO25: Amgen, Zai Lab detail reduced survival benefit in stomach cancer trial news2025-10-19T22:05:02+00:00October 19th, 2025|Endpoints News|
#ESMO25: Akeso, Summit detail ivonescimab win in China for frontline lung cancernews2025-10-19T14:30:33+00:00October 19th, 2025|Endpoints News|
Exclusive: Sid Mukherjee’s Faeth nets $25M for endometrial cancer studynews2025-10-19T09:01:24+00:00October 19th, 2025|Endpoints News|
#ESMO25: Datroway, Trodelvy contest in triple negative breast cancer heats upnews2025-10-19T08:14:23+00:00October 19th, 2025|Endpoints News|
#ESMO25: Boehringer, Bayer are neck-and-neck in front-line HER2-mutant lung cancernews2025-10-18T15:00:14+00:00October 18th, 2025|Endpoints News|
#ESMO25: Padcev-Keytruda combo extends survival in Phase 3 bladder cancer trialnews2025-10-18T14:30:51+00:00October 18th, 2025|Endpoints News|
#ESMO25: Enhertu could move into ‘curative’ breast cancer setting on the strength of Phase 3 datanews2025-10-18T14:30:08+00:00October 18th, 2025|Endpoints News|
